EMA accepts Samsung Bioepis' Herceptin biosimilar application for review

4 October 2016
biosimilars_samples_large

South Korean drug developer Samsung Bioepis is closer to bringing another biosimilar to the European market – this time referencing the breast and gastric cancer drug Herceptin (trastuzumab).

The company, a joint venture between Korean conglomerate Samsung and US biotech Biogen (Nasdaq: BIIB), has had its Marketing Authorization Application (MAA) accepted by the European Medicines Agency (EMA) for the SB3 biosimilar candidate referencing the branded biologic sold by Genentech, a subsidiary of Swiss drug giant, Roche (VTX: ROG).

"If approved, we hope our affordable, high-quality medicine will help realize the promise of biosimilars for breast cancer patients across Europe"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biosimilars